Boulevard Bio Enters Agreement to License METiS (7666.HK)'s Trispecific T-cell Engager 'MTS-128'
First Commercial Validation of AI-Based NanoForge Platform
Boulevard Bio, a newly established biotech company founded by Deerfield Management, a U.S.-based healthcare-focused investment firm, has entered into a global exclusive license agreement with METiS TechBio (7666.HK) for 'MTS-128,' a next-generation preclinical candidate. This deal is considered a major milestone, demonstrating the commercial viability of METiS TechBio's proprietary AI-based protein design and NanoForge platform. MTS-128 is a trispecific T-cell engager (TCE) that binds to three different antigens simultaneously, surpassing existing bispecific antibody technologies. This strategy aims to simultaneously suppress the multifaceted mechanisms of complex autoimmune diseases, maximizing therapeutic efficacy.
Next-Generation Modality for Autoimmune Disease Treatment
The biopharma industry is witnessing a paradigm shift, expanding T-cell engager technology, previously focused on oncology, to the treatment of autoimmune diseases. While conventional autoimmune treatments rely on broad immunosuppression, new modalities like MTS-128 can precisely target and eliminate or modulate disease-causing cells. In particular, it is emerging as an alternative to overcome the high production costs and limited ease of administration associated with CAR-T cell therapies that target existing autoimmune-inducing cells. The industry expects that the commercialization of these cell-engaging technologies will simultaneously provide clinical benefits, such as shortening the dosing cycle and reducing side effects for patients.
Performance-Based Structure and Strategic Financial Model
The total transaction value of this license agreement is $1.6 billion (USD 1.6B), but the upfront payment is $20 million (USD 20M). The remaining $1.58 billion (USD 1.58B) is structured as milestone payments tied to development, regulatory approval, and commercialization achievements, as well as tiered royalties based on net sales after commercialization. This reflects a typical high-risk, high-return biopharma pipeline acquisition strategy, minimizing initial financial burden and providing value based on the efficacy of late-stage clinical data. With the full support of Deerfield Management, Boulevard Bio is expected to rapidly advance the candidate through subsequent toxicology studies and the Investigational New Drug (IND) application process.
Competitive Landscape for Capturing a $110 Billion Market
The global autoimmune disease therapeutics market exceeded $110 billion (USD 110B) in 2025 and is expected to continue to expand with a consistent annual growth rate through 2033. To capture this vast market, Cullinan Therapeutics (CGEM) is leading the market by conducting a Phase 1 clinical trial of 'CLN-978,' a CD19xCD3 bispecific TCE for systemic lupus erythematosus (SLE). Boulevard Bio plans to leverage METiS's trispecific design advantage to secure a dominant position by establishing a broad therapeutic window and ensuring safety, despite being a late entrant. The approval of clinical entry by the U.S. Food and Drug Administration (FDA) will be the first test to determine the speed of market penetration.
This agreement represents a strategic move to secure a leading position in the next-generation autoimmune disease modality market through the global transfer of rights for 'MTS-128,' a trispecific T-cell engager (TCE) in the preclinical stage. In the short term, the key milestones are the approval of the Investigational New Drug (IND) application by the U.S. FDA and the initiation of Phase 1 clinical trials. In the medium to long term, a comparison of clinical efficacy with 'CLN-978,' the CD19/CD3-targeting bispecific candidate of Cullinan Therapeutics (CGEM), a leading competitor, will be essential. In the global autoimmune disease therapeutics market, valued at approximately $110 billion in 2025, demonstrating a superior safety profile that can replace existing biologics will be the key to commercial success. From an investor's perspective, the performance-based milestone payment structure, which amounts to $1.58 billion, representing approximately 98% of the $20 million upfront payment, warrants close monitoring for its impact on the valuation of METiS TechBio (7666.HK).